These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 1886289)
1. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Inatomi N; Nagaya H; Takami K; Shino A; Satoh H Jpn J Pharmacol; 1991 Apr; 55(4):437-51. PubMed ID: 1886289 [TBL] [Abstract][Full Text] [Related]
2. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418 [TBL] [Abstract][Full Text] [Related]
3. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178 [TBL] [Abstract][Full Text] [Related]
4. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats. Sekiguchi H; Hamada K; Taga F; Nishino K Arzneimittelforschung; 1993 Feb; 43(2):134-8. PubMed ID: 8096133 [TBL] [Abstract][Full Text] [Related]
5. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs. Nagaya H; Inatomi N; Satoh H Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288 [TBL] [Abstract][Full Text] [Related]
6. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Barradell LB; Faulds D; McTavish D Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017 [TBL] [Abstract][Full Text] [Related]
7. [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion]. Inatomi N; Murakami I; Asano S; Inada I; Satoh H Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):333-43. PubMed ID: 9017687 [TBL] [Abstract][Full Text] [Related]
8. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495 [TBL] [Abstract][Full Text] [Related]
9. Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. Umeda N; Miki K; Hoshino E J Clin Gastroenterol; 1995; 20 Suppl 1():S17-23. PubMed ID: 7673609 [TBL] [Abstract][Full Text] [Related]
10. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. Sakaguchi M; Ashida K; Umegaki E; Miyoshi H; Katsu K J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334 [TBL] [Abstract][Full Text] [Related]
11. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Satoh H Curr Pharm Des; 2013; 19(1):67-75. PubMed ID: 22950496 [TBL] [Abstract][Full Text] [Related]
12. Effect of lansoprazole on peptic ulcers. Ohashi T; Sakata J; Haraguchi Y; Eto T J Clin Gastroenterol; 1995; 20 Suppl 2():S83-5. PubMed ID: 7594350 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents. Kubo K; Oda K; Kaneko T; Satoh H; Nohara A Chem Pharm Bull (Tokyo); 1990 Oct; 38(10):2853-8. PubMed ID: 2076571 [TBL] [Abstract][Full Text] [Related]
14. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Spencer CM; Faulds D Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761 [TBL] [Abstract][Full Text] [Related]
15. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. Ogawa N Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals. Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863 [TBL] [Abstract][Full Text] [Related]
17. Effect of a novel xanthine derivative on experimental ulcers in rats. Tanaka T; Morioka Y; Gebert U Arzneimittelforschung; 1993 May; 43(5):558-62. PubMed ID: 8329000 [TBL] [Abstract][Full Text] [Related]
18. [Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats]. Murakami I; Asano S; Yukishige K; Nagaya H; Satoh H; Inatomi N Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):323-32. PubMed ID: 9017686 [TBL] [Abstract][Full Text] [Related]
19. Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Kuwayama H; Matsuo Y; Eastwood GL Am J Med; 1991 Aug; 91(2A):15S-19S. PubMed ID: 1882902 [TBL] [Abstract][Full Text] [Related]
20. Factors affecting quality of ulcer healing after lansoprazole treatment. Ito G; Nakagawara M; Watanabe F; Ooi S; Nawano M; Hanai H; Kaneko E J Clin Gastroenterol; 1995; 20 Suppl 2():S62-6. PubMed ID: 7594344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]